Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeFRA:N2U0 -6.03%9 PB Ratio is 3.76 as of Sep. 01, 2026. GuruFocus rates FRA:N2U0 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 1,213 Biotechnology companies, Adlai Nortye ranks worse than 63.73% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-01), Adlai Nortye's share price is €10.90. Adlai Nortye's Book Value per Share for the quarter that ended in Jun. 2026 was €2.90. Hence, Adlai Nortye's PB Ratio of today is 3.76.
The historical rank and industry rank for Adlai Nortye's PB Ratio or its related term are showing as below:
FRA:N2U0'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.25
Current: 4.25
During the past 5 years, Adlai Nortye's highest PB Ratio was 4.25. The lowest was 0.00. And the median was 0.00.
FRA:N2U0's PB Ratio is ranked worse than 63.73% of 1213
companies
in the Biotechnology industry
Industry Median: 2.89
vs FRA:N2U0: 4.25
During the past 12 months, Adlai Nortye's average Book Value Per Share Growth Rate was 1451.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 68.80% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Adlai Nortye was 68.80% per year. The lowest was 68.80% per year. And the median was 68.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Adlai Nortye PB Ratio Related Terms
Adlai Nortye PB Ratio Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's PB Ratio distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Adlai Nortye's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Adlai Nortye (FRA:N2U0) has a PB Ratio of 3.76 as of Sep. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #773 out of 1213 companies in the Biotechnology industry, placing it in the top 63.7%.
Is Adlai Nortye's PB Ratio too high?
Adlai Nortye's current PB Ratio is 3.76. The Biotechnology industry median PB Ratio is 2.89. Adlai Nortye's value of 3.76 is 30.1% above this industry median. Based on the distribution chart, Adlai Nortye ranks #773 out of 1213 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adlai Nortye has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's PB Ratio compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #773 out of 1213 companies for PB Ratio. This places Adlai Nortye in the lower half of its industry. The industry median PB Ratio is 2.89. Adlai Nortye's value of 3.76 is 30.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,213 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current PB Ratio of 3.76 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current PB Ratio is 3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (FRA:N2U0) has a current PB Ratio of 3.76. The current PB Ratio is 3.76 and 30.1% above the Biotechnology industry median of 2.89. Adlai Nortye's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Adlai Nortye (FRA:N2U0), the current PB Ratio is 3.76 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
9GF Score
Get the complete analysis for FRA:N2U0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N2U0 has been successfully added to your 
